Valproate and Divalproex
Jump to navigation
Jump to search
| Drug monograph · NCLEX study reference | |
| Trade names | Depakote |
|---|---|
| Therapeutic class | Anticonvulsant, mood stabilizer, migraine prophylaxis |
| Pharmacologic class | Carboxylic acid derivative |
| Onset / peak / duration | Effect over days; ER once daily. |
| Half-life / level | Half-life 9 to 16 hours; therapeutic level 50 to 100 mcg/mL. |
| Routes | PO (oral), IV |
| High-alert (ISMP) | No |
| Black box warning | Yes (see Safety) |
| Antidote / reversal | L-carnitine for hyperammonemia; supportive care. |
| Pregnancy / lactation | Avoid in pregnancy when possible. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Valproate and Divalproex (brand name Depakote) — Anticonvulsant, mood stabilizer, migraine prophylaxis; Carboxylic acid derivative.
Identification
- Therapeutic class: Anticonvulsant, mood stabilizer, migraine prophylaxis.
- Pharmacologic class: Carboxylic acid derivative.
Pharmacology
- Mechanism of action: Increases GABA and blocks sodium channels.
- Onset / peak / duration: Effect over days; ER once daily.
- Half-life / therapeutic level: Half-life 9 to 16 hours; therapeutic level 50 to 100 mcg/mL.
Clinical use
- Indications: Seizures, bipolar mania, migraine prophylaxis.
- Usual dose, route, frequency: PO or IV, titrated by level; ER once daily.
- Maximum dose / adjustments: Titrate to level; reduce in hepatic disease.
Safety
- Contraindications: Hepatic disease, urea cycle disorders, mitochondrial disorders, pregnancy for migraine.
- Black box warning: Hepatotoxicity (especially in young children), teratogenicity (neural tube defects and reduced IQ), and life-threatening pancreatitis.
- Interactions: Raises lamotrigine and phenobarbital levels, warfarin, aspirin, carbapenems (lower valproate level), other antiepileptics.
- Pregnancy / lactation: Avoid in pregnancy when possible.
- High-alert: No.
Adverse effects
- Common side effects: Nausea, sedation, weight gain, tremor, hair thinning.
- Serious effects to report: Hepatotoxicity, pancreatitis, thrombocytopenia, hyperammonemia (confusion).
- Antidote / reversal: L-carnitine for hyperammonemia; supportive care.
Nursing process
- Assessment before administration: LFTs, CBC and platelets, ammonia if symptomatic, pregnancy status.
- Interventions during therapy: Monitor for bleeding and abdominal pain; check levels.
- Monitor: Drug level, LFTs, platelets, ammonia, seizure or mood control.
- Evaluation / expected outcome: Seizure, mood, or migraine control.
Patient teaching
- Patient teaching: Report abdominal pain, yellowing, easy bruising; reliable contraception.
- Notify provider if: Severe stomach pain, vomiting, jaundice, unusual bruising, confusion.
- Administration tips: With food; swallow ER whole; do not use carbonated drinks with the sprinkle form.